Nifty 17186.5 (-1.24%)
Sensex 57814.46 (-1.11%)
Nifty Bank 36122.4 (-1.06%)
Nifty IT 35971.7 (-0.51%)
Nifty Financial Services 17790.8 (-1.07%)
Adani Ports 737.40 (-0.23%)
Asian Paints 3110.40 (-2.21%)
Axis Bank 671.20 (-0.72%)
B P C L 385.55 (1.77%)
Bajaj Auto 3288.55 (-1.20%)
Bajaj Finance 7076.45 (-1.45%)
Bajaj Finserv 17517.50 (-1.36%)
Bharti Airtel 718.60 (-1.90%)
Britannia Inds. 3553.50 (-0.70%)
Cipla 913.20 (-0.87%)
Coal India 159.40 (0.06%)
Divis Lab. 4755.35 (-0.46%)
Dr Reddys Labs 4602.00 (-1.30%)
Eicher Motors 2459.00 (0.30%)
Grasim Inds 1705.10 (-1.09%)
H D F C 2771.95 (-1.28%)
HCL Technologies 1172.75 (-1.01%)
HDFC Bank 1510.30 (-1.01%)
HDFC Life Insur. 692.10 (-1.87%)
Hero Motocorp 2464.80 (-0.32%)
Hind. Unilever 2341.55 (-1.75%)
Hindalco Inds. 425.40 (-1.55%)
I O C L 121.90 (1.04%)
ICICI Bank 716.10 (-0.87%)
IndusInd Bank 949.45 (0.41%)
Infosys 1739.20 (-0.52%)
ITC 221.85 (-1.60%)
JSW Steel 644.20 (-0.39%)
Kotak Mah. Bank 1906.20 (-2.96%)
Larsen & Toubro 1805.60 (0.92%)
M & M 836.95 (-1.48%)
Maruti Suzuki 7221.90 (-1.41%)
Nestle India 19325.45 (-0.91%)
NTPC 126.90 (-1.40%)
O N G C 145.60 (1.11%)
Power Grid Corpn 206.00 (-3.96%)
Reliance Industr 2402.80 (-3.22%)
SBI Life Insuran 1167.85 (-1.70%)
Shree Cement 25889.00 (-1.52%)
St Bk of India 472.05 (-1.04%)
Sun Pharma.Inds. 749.60 (-2.17%)
Tata Consumer 774.05 (0.10%)
Tata Motors 479.60 (0.10%)
Tata Steel 1119.65 (0.65%)
TCS 3640.15 (-0.08%)
Tech Mahindra 1596.50 (-2.03%)
Titan Company 2365.30 (-0.89%)
UltraTech Cem. 7339.65 (0.22%)
UPL 715.00 (2.41%)
Wipro 641.10 (-0.88%)
INFY

Indoco Remedies Ltd.

₹402.05
Not a customer?

Open free demat account
& trade instantly

Investment Ratings

As per analysts rating in the last 6 months, the recommendation is to HOLD Indoco Remedies

  • Master Rating:
  • Indoco Remedies has an operating revenue of Rs. 1,411.05 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 11% is healthy, ROE of 12% is good. The company has a reasonable debt to equity of 13%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 59 which is a POOR score indicating inconsistency in earnings, a RS Rating of 32 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 146 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Indoco Remedies Ltd Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Ratings

Eps And Sales Estimates

Indoco Remedies Ltd Synopsis

NSE-Medical-Diversified

Indoco Remedies is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1240.30 Cr. and Equity Capital is Rs. 18.43 Cr. for the Year ended 31/03/2021. Indoco Remedies Ltd. is a Public Limited Listed company incorporated on 23/08/1947 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L85190MH1947PLC005913 and registration number is 005913.
  • Market Cap

    INR 3,715.49 Cr

  • Sales

    INR 1,409.87 Cr

  • Shares in Float

    3.78 Cr

  • No of Funds

    67 K

  • Yield

    0.38%

  • Book Value

    4.76

  • U/D Vol Ratio

    0.5

  • LTDebt/Equity

    13%

  • Alpha

    0.07

  • Beta

    0.82

Indoco Remedies Ltd Ownership
Indoco Remedies Ltd Management

Indoco Remedies Ltd Financials

INDICATORMar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Total ShareHolders Funds Annual Cr 768.9288680.1611661.0832675.5588651.8795
Fixed Assets Annual Cr 638.0133640.3206652.9502624.2851530.3817
Total Non Current Assets Annual Cr 694.6194710.5462721.7959700.8463627.057
Total Current Assets Annual Cr 621.9485561.764536.5038537.1519570.1785
Total Assets Annual Cr 1316.56791272.31021258.29971237.99821197.2355
INDICATORMar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Book Value Per Share Annual Rs 83.442673.809871.739473.310270.7406
ROE Annual % 12.013.56-0.426.0911.88
ROCE Annual % 16.916.751.388.7612.08
Total Debt to Total Equity Annual -----
EBDIT Annual Margin % 18.2711.378.5613.4414.99

Indoco Remedies Ltd Technicals

EMA & SMA

CURRENT PRICE

402.05 (1.16)

    • Bullish Moving Averages 6
    • Bearish Moving Averages 10

EMA

  • 20 Day

    413.1

  • 50 Day

    431.87

  • 100 Day

    428.27

  • 200 Day

    394.81

Indoco Remedies Ltd Resistance and support

392.82 PIVOT

  • First Resistance

    406.64

  • Second Resistance

    415.82

  • Third Resistance

    429.64

  • First Support

    383.64

  • Second Support

    369.82

  • Third Support

    360.64

  • RSI

    39.26

  • MFI

    35.84

  • MACD

    -15.93

  • MACD signal line

    -14.44

Indoco Remedies Ltd Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 230,351 7,090,204 30.78%
Week 194,897 8,425,389 43.23%
1 Month 183,242 8,458,444 46.16%
6 Month 493,777 13,514,668 27.37%

Indoco Remedies Ltd Price change analysis

-55.2

Over 1 month

Low High
376.35 466.9

-84.25

Over 3 month

Low High
376.35 513.65

5.5

Over 6 months

Low High
376.35 530.25

118.6

Over Year

Low High
251.9 530.25

Similar Stocks

News

INDOCO REMEDIES LTD. - 532612 - Announcement under Regulatio

Intimation of Schedule of Analyst / Institutional Investors Meet Read More

INDOCO REMEDIES LTD. - 532612 - Announcement under Regulatio

Intimation of Schedule of Analyst / Institutional Investors Meet Read More

INDOCO REMEDIES LTD. - 532612 - Related Party Transactions P

Related party transactions pursuant to Reg 23(9) of SEBI (LODR) Reg, 2015 (Listing Regulations) Read More

Accumulate Indoco Remedies; target of Rs 480: Prabhudas Lill

Prabhudas Lilladher recommended accumulate rating on Indoco Remedies with a target price of Rs 480 in its research report dated November 04, Read More

INDOCO REMEDIES LTD. - 532612 - Audio Recording Of Conferenc

Audio recording of Conference Call held on November 02, 2021 Read More

Blogs

FAQs